comparemela.com
Home
Live Updates
Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting : comparemela.com
Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months)
Related Keywords
Chicago ,
Illinois ,
United States ,
Sweden ,
Hall On ,
Orebro ,
American ,
Jean Luc Van Laethem ,
Sumeet Ambarkhane ,
Peter Ellmark ,
Frank Hoerning Andersen ,
Aptevo Therapeutics Inc ,
Orion Corporation ,
American Society Of Clinical Oncology ,
Cohesion Bureau ,
Market Research ,
Biotheus Inc ,
Shanghai Henlius Biotech Inc ,
Alligator Bioscience ,
Clinical Oncology ,
Annual Meeting ,
Objective Response Rate ,
Response Evaluation Criteria ,
Solid Tumors ,
Overall Survival ,
Gastrointestinal Cancer Gastroesophageal ,
Shanghai Henlius Biotech ,
Nasdaq Stockholm ,
Present Positive Phase ,
Pancreatic Cancer ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.